Not only may patients and their close relatives become aware of being at increased risk of developing various cancer types, pathogenic BRCA1/2 variants are also treatment targets for poly ADP-ribose polymerase (PARP) inhibitors (33). The gene discussed is BRCA1; the disease is cancer.